LY3499446   Click here for help

GtoPdb Ligand ID: 12066

Synonyms: compound B [WO2022002018A1] | LY-3499446
Compound class: Synthetic organic
Comment: LY3499446 is a direct inhibitor of oncogenic KRAS mutant G12C that was developed for anticancer potential [1].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 116.48
Molecular weight 486.08
XLogP 3.84
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C=CC(=O)N1CCN(CC1)c1ncnc2c1cc(Cl)c(c2F)c1ccc(c2c1nc(s2)N)F
Isomeric SMILES C=CC(=O)N1CCN(CC1)c1ncnc2c(c(c(cc12)Cl)c1c2c(c(cc1)F)sc(n2)N)F
InChI InChI=1S/C22H17ClF2N6OS/c1-2-15(32)30-5-7-31(8-6-30)21-12-9-13(23)16(17(25)18(12)27-10-28-21)11-3-4-14(24)20-19(11)29-22(26)33-20/h2-4,9-10H,1,5-8H2,(H2,26,29)
InChI Key YNBBKDMAVRSYRE-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
LY3499446 entered early stage clinical evaluation, but the study was terminated due to unexpected toxic effects that precluded further development.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04165031 A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation Phase 1/Phase 2 Interventional Eli Lilly and Company